• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肿瘤内肿瘤坏死因子α可改善免疫治疗。

Intratumoral TNFα improves immunotherapy.

作者信息

Johansson Anna, Hamzah Juliana, Ganss Ruth

机构信息

Western Australian Institute for Medical Research; University of Western Australia Centre for Medical Research; Laboratory for Cancer Medicine; Perth, WA Australia.

出版信息

Oncoimmunology. 2012 Nov 1;1(8):1395-1397. doi: 10.4161/onci.20981.

DOI:10.4161/onci.20981
PMID:23243605
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3518514/
Abstract

Solid tumors are frequently resistant to immunotherapy. We demonstrated that low-dose tumor necrosis factorα (TNFα), when directly targeted to the tumor environment, exerts dual effects by improving vessel functionality and activating immune cells. This vascular remodeling in an inflammatory context enhances active immunotherapy and promotes tumor regression.

摘要

实体瘤通常对免疫疗法有抗性。我们证明，低剂量肿瘤坏死因子α（TNFα）直接作用于肿瘤环境时，可通过改善血管功能和激活免疫细胞发挥双重作用。在炎症背景下的这种血管重塑增强了主动免疫疗法并促进肿瘤消退。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/311c/3518514/f175aa1b94ff/onci-1-1395-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/311c/3518514/f175aa1b94ff/onci-1-1395-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/311c/3518514/f175aa1b94ff/onci-1-1395-g1.jpg

相似文献

1
Intratumoral TNFα improves immunotherapy.肿瘤内肿瘤坏死因子α可改善免疫治疗。
Oncoimmunology. 2012 Nov 1;1(8):1395-1397. doi: 10.4161/onci.20981.
2
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.肿瘤靶向 TNFα 稳定肿瘤血管并增强主动免疫治疗。
Proc Natl Acad Sci U S A. 2012 May 15;109(20):7841-6. doi: 10.1073/pnas.1118296109. Epub 2012 Apr 30.
3
Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.肿瘤微环境重塑通过瘤内溶瘤痘苗病毒增强免疫检查点阻断的疗效。
Clin Cancer Res. 2019 Mar 1;25(5):1612-1623. doi: 10.1158/1078-0432.CCR-18-1932. Epub 2018 Dec 11.
4
Vascular-targeted TNFα improves tumor blood vessel function and enhances antitumor immunity and chemotherapy in colorectal cancer.血管靶向 TNFα 可改善肿瘤血管功能，增强结直肠癌的抗肿瘤免疫和化疗效果。
J Control Release. 2015 Jul 28;210:134-46. doi: 10.1016/j.jconrel.2015.05.282. Epub 2015 May 21.
5
Modulation of pericytes by a fusion protein comprising of a PDGFRβ-antagonistic affibody and TNFα induces tumor vessel normalization and improves chemotherapy.包含 PDGFRβ 拮抗亲和体和 TNFα 的融合蛋白对周细胞的调节可诱导肿瘤血管正常化并改善化疗。
J Control Release. 2019 May 28;302:63-78. doi: 10.1016/j.jconrel.2019.03.018. Epub 2019 Mar 28.
6
De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors.肿瘤内淋巴结构的从头诱导和血管正常化增强了耐药肿瘤的免疫治疗。
Nat Immunol. 2017 Nov;18(11):1207-1217. doi: 10.1038/ni.3836. Epub 2017 Sep 11.
7
Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency.肿瘤血管靶向 TNFα 治疗：逆转微环境无能和增强抗肿瘤效率。
Curr Med Chem. 2020;27(25):4233-4248. doi: 10.2174/0929867325666180904121118.
8
Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.在同基因J558L BALB/c骨髓瘤模型中，基于抗体将肿瘤坏死因子（L19-TNFα）和白细胞介素-2（L19-IL2）递送至肿瘤相关血管具有强大的免疫和抗癌活性。
J Cancer Res Clin Oncol. 2018 Mar;144(3):499-507. doi: 10.1007/s00432-017-2564-6. Epub 2018 Jan 11.
9
Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy.瘤内肽注射增强了细胞毒性 T 淋巴细胞识别的肿瘤细胞抗原性：提高抗原特异性癌症免疫治疗的一种潜在选择。
Cancer Immunol Immunother. 2013 Apr;62(4):639-52. doi: 10.1007/s00262-012-1366-6. Epub 2012 Nov 11.
10
T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors.T 细胞重定向至次要组织相容性抗原可指导肿瘤内 TNFα 的表达，并增强过继细胞疗法治疗实体瘤。
Cancer Res. 2017 Feb 1;77(3):658-671. doi: 10.1158/0008-5472.CAN-16-0725. Epub 2016 Nov 21.

引用本文的文献

1
Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling.通过基质重塑诱导癌症中的三级淋巴结构。
Front Immunol. 2021 May 27;12:674375. doi: 10.3389/fimmu.2021.674375. eCollection 2021.
2
Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors.经TCR工程改造的T细胞在肿瘤内产生白细胞介素18（IL18）而非白细胞介素12（IL12），这种产生无毒，且能对抗实体瘤的免疫逃逸。
Oncoimmunology. 2017 Oct 11;7(1):e1378842. doi: 10.1080/2162402X.2017.1378842. eCollection 2017.
3
Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF.

本文引用的文献

1
Remodeling of tumor stroma and response to therapy.肿瘤基质的重构与治疗反应。
Cancers (Basel). 2012 Mar 27;4(2):340-53. doi: 10.3390/cancers4020340.
2
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.肿瘤靶向 TNFα 稳定肿瘤血管并增强主动免疫治疗。
Proc Natl Acad Sci U S A. 2012 May 15;109(20):7841-6. doi: 10.1073/pnas.1118296109. Epub 2012 Apr 30.
3
Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy.
肿瘤血管靶向剂NGR-TNF的抗转移活性
Clin Exp Metastasis. 2015 Mar;32(3):289-300. doi: 10.1007/s10585-015-9704-7. Epub 2015 Feb 4.
4
Defects in the acquisition of tumor-killing capability of CD8+ cytotoxic T cells in streptozotocin-induced diabetic mice.链脲佐菌素诱导的糖尿病小鼠中CD8 + 细胞毒性T细胞杀伤肿瘤能力获得方面的缺陷。
PLoS One. 2014 Nov 12;9(11):e109961. doi: 10.1371/journal.pone.0109961. eCollection 2014.
5
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu.T 细胞受体工程化 T 细胞在治疗实体瘤上面临新的挑战：抗原选择、T 细胞功能和肿瘤微环境的致敏。
Front Immunol. 2013 Nov 8;4:363. doi: 10.3389/fimmu.2013.00363. eCollection 2013.
6
Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.多肽介导的细胞因子靶向肿瘤血管：NGR-hTNF 为例。
BioDrugs. 2013 Dec;27(6):591-603. doi: 10.1007/s40259-013-0048-z.
针对肿瘤内新生血管的 TNF-α 靶向治疗可增强淋巴细胞浸润，并提高免疫治疗的治疗潜力。
J Immunol. 2012 Mar 15;188(6):2687-94. doi: 10.4049/jimmunol.1101877. Epub 2012 Feb 8.
4
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.HRG 通过下调 PlGF 诱导巨噬细胞极化和血管正常化来抑制肿瘤生长和转移。
Cancer Cell. 2011 Jan 18;19(1):31-44. doi: 10.1016/j.ccr.2010.11.009. Epub 2011 Jan 6.
5
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.抗血管生成药物可以增加淋巴细胞浸润到肿瘤中，并增强癌症过继免疫治疗的效果。
Cancer Res. 2010 Aug 1;70(15):6171-80. doi: 10.1158/0008-5472.CAN-10-0153. Epub 2010 Jul 14.
6
Vascular normalization in Rgs5-deficient tumours promotes immune destruction.Rgs5基因缺陷型肿瘤中的血管正常化促进免疫破坏。
Nature. 2008 May 15;453(7193):410-4. doi: 10.1038/nature06868. Epub 2008 Apr 16.
7
5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy.5,6-二甲基呫吨酮-4-乙酸对非免疫原性肿瘤的治疗不能与主动或被动CD8 + T细胞免疫疗法产生协同作用。
Immunol Cell Biol. 2006 Aug;84(4):383-9. doi: 10.1111/j.1440-1711.2006.01448.x.
8
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas.肿瘤血管靶向剂NGR-TNF对小鼠淋巴瘤肿瘤微环境的影响。
Invest New Drugs. 2006 Jan;24(1):27-36. doi: 10.1007/s10637-005-4540-2.
9
Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.通过血管靶向和屏障改变提高化疗药物在肿瘤中的渗透。
J Clin Invest. 2002 Aug;110(4):475-82. doi: 10.1172/JCI15223.
10
Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.T细胞疗法与炎症触发因素的联合可诱导血管重塑并根除肿瘤。
Cancer Res. 2002 Mar 1;62(5):1462-70.